Nanomedicine company BIND Therapeutics has appointed Andrew Hirsch as president and chief executive, confirming him in the roles he has held on an interim basis since March.
Prior to that Hirsch, who has now also been elected to BIND’s board of directors, served as the Cambridge, Massachusetts-based company’s chief operating officer and chief financial officer.
Before joining BIND Hirsch spent almost 10 years at Biogen, rising to VP of corporate strategy and M&A. Commenting on his role at BIND Hirsch said: “I’m excited by the opportunity to continue working with our employees, the senior management team and the Board as we develop therapies with the potential to have a profound impact on the treatment of serious diseases.
“Our nanomedicine platform, one of the most advanced in the industry, enables independent modulation of targeting, cellular trafficking and drug release. Together, these properties enable us to engineer novel therapeutic approaches that can lead to breakthrough therapies.”
The clinical-stage firm is developing targeted and programmable therapeutics called Accurins that it is working on developing into a pipeline of treatments for haematological and solid tumours. Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.